Abstract:Aims Aspirin is widely used in the primary and secondary prevention of cardiovascular diseases. Nevertheless, the responses to aspirin administration vary from one patient to another, and there is a lack of efficient and platelet-specific method correlated well with clinical outcomes. The aim of our study was to make comparisons between 2 established methods of aspirin response evaluation)—measurement of urinary 11-dehydrothromboxane B2 (11dhTxB2) and plasma Light Transmission Aggregometry (LTA) assay—in aged patients with coronary artery disease (CAD), and examinethe relationship between AR and clinical outcomes. Methods A total of 145 aged patients with CAD on low-dose aspirin (100 mg/d) therapy were enrolled in this study. All patients were measuredby urinary11dhTxB2 and platelet aggregation. Aspirin response was assessed via urinary 11dhTxB2 measurement and plasma LTAassay. AspirinResistance (AR) was defined as urinary11dhTxB2 >1500 pg/mg or 0.5 mg/ml AA-induced platelet aggregation ≥ 15.07%. The Spearman correlation coefficients andkappa statistics were calculated to assess correlation and agreement between the2 tests. The measured clinical outcome was defined as the occurrence of cardiovascular events and death. Results Prevalence of aspirin non-responders was 32.1% and 13.2%, according to urinary 11dhTxB2 measurement and LTA assay, respectively. Poor correlation in the results between the 2 tests was observed (r = 0.135, p = 0.151). Besides, the correlation between the 2 methods and AR was weak (kappa = 0.113, p = 0.113). With a mean follow-up time of 12 months, the clinical outcomes occurred more frequently in AR patients based on urinary 11dhTxB2 measurement as compared with normal aspirin response patients (18% vs 2%, OR: 8.8, 95% CI: 1.18~65.4, p = 0.037). Conclusions Our research observed poor correlation and lack of agreement between the 2 tests. Urinary 11dhTxB2 measurement might be a better predictor in the risk of cardiovascular events and death as compared to LTA assay. Nevertheless, development of efficient and inexpensive platelet function tests, which should also have a good correlation with clinical outcomes was necessary.

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding

ASSA14-03-42 Urinary 11-dehydro-Thromboxane B2 (11dhTxB2) and aspirin response in aged patients with coronary artery disease

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

Urinary thromboxane and risk of cardiovascular events: role of aspirin

ASSA14-03-38 Comparison of Urinary11-DehydrothromboxaneB2 detection and Plasma LTA Assay for evaluating aspirin response in the Aged Patients with Coronary Artery Disease

Comparison Between Urinary 11-Dehydrothromboxane B2 Detection and Platelet Light Transmission Aggregometry (lta) Assays for Evaluating Aspirin Response in Elderly Patients with Coronary Artery Disease

Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention

Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease

Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic …

Chronic Application of Low-Dose Aspirin Affects Multiple Parameters of Three Blood Cellular Types and Antithrombin Activity: A 1:1:1 Propensity Score Matching Analysis

[Correlation Between the Level of the Urinary 11-Dehydrothromboxane B2 and the Clinical Efficacy of Aspirin in Patients with Type 2 Diabetes and Coronary Artery Disease].

Short-term Efficacy and Safety of Personalized Antiplatelet Therapy for Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack: A Randomized Clinical Trial

Reduced Variability to Aspirin Antiplatelet Effect by the Coadministration of Statins in High-Risk Patients for Cardiovascular Disease

Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study

Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

The Effect of Different Dosage of Aspirin on Inflammatory Biomarkers and Prognosis in Acute Coronary Syndrome

Multi-parameter Assessment of Platelet Inhibition and Its Stability During Aspirin and Clopidogrel Therapy

Risk of Upper Gastrointestinal Bleeding With Low-Dose Acetylsalicylic Acid Alone and in Combination With Clopidogrel and Other Medications